AUCs further improved to 0.800, 0.827, and 0.793 for the outcomes of all-cause dementia, AD, and VD, respectively, when APOE ε4 carrier status was added to the CAIDE model (Model 2). This evidence concerns the gene APOE and Alzheimer disease.